Danish diabetes biotech Zealand Pharma has started its initial public offering in the US at Nasdaq Global Select Market. It plans to raise US$75m to fund clinical trails.
Italian pharma company Chiesi Farmaceutici withdraws from a co-development agreement with gene therapy pioneer Uniqure. This will add US$1.5m to Uniqures expenses this year.
French immunotherapy specialist Neovacs raises 6€m from three US institutional investors. The private placement involves the issuance of more than 9 million shares.
Johnson & Johnson has entered a new deal with Danish biotech Bavarian Nordic worth up to US$879m to develop vaccine regimens against hepatitis B and HIV.
UKs biggest pharma firm announced it will save an additional £1bn each year by 2020. 80% of the pharmaceutical R&D pipeline expenses will be directed towards two current (Respiratory and HIV/infectious diseases) and two potential (Oncology and Immuno-inflammation) priority areas.
French yeast manufacturer Lesaffre acquires an equity stake in US biotech company Intralytix. Paying more than €15m, Lesaffre gains valuable insights into the development and commercialisation of bacteriophage-based products.
French Antabio receives funding by the Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X). Including future milestone payments, Antabio is eligible for up to €7.6m for their treatment of chronic infections in cystic fibrosis patients.
French vaccines expert Valneva SE announced that the FDA has granted Fast Track designation for its Lyme borreliosis vaccine candidate VLA15.
After 3 years of collaboration Roche has ended a cancer deal with the Spanish biotech company Oryzon granting the rights to their cancer candidate ORY-1001.
Belgian nanobody-developer Ablynx NV now also works together with French pharma company Sanofi. The deal is potentially worth €2.4bn but comes with an upfront payment of just €23m. The partners will initially focus on therapeutics for the treatment of various immune-mediated inflammatory diseases.